Myomo makes and sells the MyoPro, a powered arm brace for people with partial arm paralysis from stroke, spinal cord injury, brachial plexus injury, or other neurological conditions. The device uses EMG sensors to detect faint muscle signals from the user's weakened limb, then activates small motors to move the arm and hand — the user initiates and controls all movement through their own muscle signals. The MyoPro is custom-fabricated for each patient using 3D printing. The flagship product, the MyoPro Motion G, accounts for roughly 96% of product revenue. Myomo sells primarily through three channels: direct billing (~73% of revenue), where Myomo's own clinical staff fits the device and bills insurance directly; an O&P channel (~9%), where independent orthotics and prosthetics clinics handle fitting and billing and buy the device from Myomo at wholesale; and international (~18%), primarily through O&P partners in Germany. Revenue is generated on a per-unit basis — there is no recurring revenue model. The key economics depend heavily on insurance reimbursement, with Medicare reimbursing roughly $68,800 for the Motion G. Insurance authorization is operationally complex; Medicare Part B patients require no pre-authorization and move through the revenue cycle fastest, while Medicare Advantage plans carry high initial denial rates, requiring frequent appeals. Myomo's growth strategy focuses on reducing dependence on expensive direct-to-consumer advertising by building a clinical referral program, expanding the O&P channel, and broadening in-network insurance contracts.